Publication | Open Access

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer

MedicinePharmacologyTopoisomerase Ii InhibitorBronchial NeoplasmAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyLung Cancer